These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 16128193)

  • 21. [Cox-2 inhibitors in the focus. Rofecoxib as effective as the "classics"].
    MMW Fortschr Med; 2001 Nov; 143(46):50-1. PubMed ID: 11759601
    [No Abstract]   [Full Text] [Related]  

  • 22. [Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
    Blondon H
    Presse Med; 2000 Mar; 29(9):482-3. PubMed ID: 10745938
    [No Abstract]   [Full Text] [Related]  

  • 23. [New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results].
    Oliw E; Wollheim FA
    Lakartidningen; 2000 Jun; 97(24):2942-4. PubMed ID: 10900877
    [No Abstract]   [Full Text] [Related]  

  • 24. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
    Croom KF; Siddiqui MA
    Drugs; 2009 Jul; 69(11):1513-32. PubMed ID: 19634927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
    Fung HB; Kirschenbaum HL
    Clin Ther; 1999 Jul; 21(7):1131-57. PubMed ID: 10463513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharma-clinics. The drug of the month. Celecoxib (Celebrex)].
    Scheen AJ
    Rev Med Liege; 2001 Jan; 56(1):53-5. PubMed ID: 11256140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
    Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COX-2 inhibitors.
    Brooks PM; Day RO
    Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs.
    Poddubnyy D; Song IH; Sieper J
    Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S148-51. PubMed ID: 19822063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical use of COX-2 inhibitors].
    Ristić GG; Stefanović DZ
    Vojnosanit Pregl; 2001; 58(3):283-95. PubMed ID: 11548555
    [No Abstract]   [Full Text] [Related]  

  • 31. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
    Clemett D; Goa KL
    Drugs; 2000 Apr; 59(4):957-80. PubMed ID: 10804043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COX 2-selective NSAIDs: biology, promises, and concerns.
    Mandell BF
    Cleve Clin J Med; 1999 May; 66(5):285-92. PubMed ID: 10330781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
    Tindall E
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Financial interests characterize published reports on coxiber. Whom can we rely on?].
    Håkansson J
    Lakartidningen; 2002 Oct; 99(40):3930-1. PubMed ID: 12422746
    [No Abstract]   [Full Text] [Related]  

  • 35. COX-2 inhibitors. Magic bullets or merely mortal?
    Harv Health Lett; 2000 Feb; 25(4):4. PubMed ID: 10637015
    [No Abstract]   [Full Text] [Related]  

  • 36. [Trends in the treatment of rheumatic diseases].
    Trotta F; Padovan M
    Recenti Prog Med; 1999 Oct; 90(10):510-4. PubMed ID: 10592735
    [No Abstract]   [Full Text] [Related]  

  • 37. Cox-2 inhibitors: today and tomorrow.
    McMurray RW; Hardy KJ
    Am J Med Sci; 2002 Apr; 323(4):181-9. PubMed ID: 12003372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective COX-2 inhibition.
    Silas S; Clegg DO
    Bull Rheum Dis; 1999; 48(2):1-4. PubMed ID: 12024416
    [No Abstract]   [Full Text] [Related]  

  • 39. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.